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Abstract
Recently, there has been international concern at the rapid emergence of highly pathogenic strains of Staphylococcus aureus associated
with a toxin called Panton–Valentine leukocidin (PVL). In the UK, these strains are considered to be rare and mainly severe. We esti-
mate the proportion of staphylococcal infections that are caused by strains containing the PVL genes, and describe risk factors for these
infections. Three hundred and ninety consecutive S. aureus clinical isolates, submitted for routine diagnostic purposes were screened for
PVL genes. Risk factors for infection were identiﬁed from the patient medical record. 9.7% (95% CI 7.0–13.1%) of clinical isolates and
20.8% of skin and soft tissue specimens contained the genes for PVL. Methicillin-resistant S. aureus with PVL was rare (0.8% of all iso-
lates) but PVL with methicillin-sensitive S. aureus was common (9.0% of all specimens). PVL infection was more frequent in males (OR
3.0, 95% CI 1.3–7.0), and in young adults aged 20–39 years (OR 3.7, 95% CI 1.3–10.4). Over half of PVL positive S. aureus infections
originated in patients based in the community. Community-onset PVL-associated disease is common in the UK and mainly causes skin
and soft tissue infections that do not require admission to hospital. Consideration should be given to current infection control strategy,
which advocates household contact screening and decolonization on the assumption that PVL-associated disease is rare.
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Panton–Valentine leukocidin (PVL) containing strains of
Staphylococcus aureus have emerged worldwide as an impor-
tant cause of severe skin and soft tissue infections [1], nec-
rotizing pneumonia and sepsis [2,3]. These strains mainly
affect young and healthy individuals who have not had con-
tact with healthcare, suggesting that infection is acquired in
the community [4,5]. Cases of PVL containing S. aureus (PVL-
SA) pneumonia have been reported across Europe [2,6,7]
but the prevalence of PVL strains amongst isolates submitted
to national reference units is variable [1,8–11].
PVL is a cytotoxin that causes leukocyte destruction and
tissue necrosis [12]. Although there is agreement that PVL
strains are epidemiologically linked to severe skin infections
and necrotizing pneumonia [1,2], conﬂict remains over
whether PVL is itself pathogenic [13–15]. Outbreaks of PVL-
SA associated disease have been described in diverse popula-
tions such as the military, prisoners, Alaskan natives and
sports-teams [16–19] and persistent close contact is a key
factor in transmission [20]. Infection control measures focus
on good hygiene, avoiding sharing personal items and envi-
ronmental cleaning.
PVL-SA strains are considered to be rare in the UK [21].
In 2002, <2% of a sample of S. aureus isolates referred to the
UK Staphylococcal Reference Unit contained the PVL genes
[11]. This is likely to under-estimate the true burden of dis-
ease in the community because reference units only receive
a small number of highly selected isolates that are unrepre-
sentative of the whole spectrum of clinical disease. Because
PVL-SA surveillance is not systematic and current UK
national staphylococcal surveillance depends largely on speci-
mens from bacteraemias, an increase in PVL containing
strains in the community could easily pass undetected.
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We estimate the proportion of staphylococcal infections
that are caused by PVL containing strains and describe risk
factors for these infections.
Materials and Methods
Study design and setting
This prospective cross-sectional study was conducted at the
Royal Free Hampstead NHS Trust, a large teaching hospital
in North London which has approximately 900 beds and
receives approximately 700 000 patients per year. Locally,
approximately 250 000 people use the general health ser-
vices at the Trust (0.4% of the total UK population), whereas
patients using specialized services travel from all over the
country and abroad. The Microbiology laboratory receives in
the region of 400 000 clinical specimens from inpatients,
outpatients and general practice. Between 15 July and 11
September 2007 S. aureus isolates were collected from
hospital and community specimens and investigated for the
presence of the PVL genes using real-time PCR. Data were
anonymized by removing all patient-identifying details and
allocating a unique study code to each specimen, linked to
the Patient Administration System (PAS) database. Informa-
tion on hospital admission between 1 January 2006 and 11
September 2007 was obtained from the PAS database for
each patient. Ethical approval was obtained from the Royal
Free Hospital and Medical School Local Research Ethics
Committee (reference 07/H0720/146).
Inclusion and exclusion criteria
Three hundred and ninety consecutive, unselected S. aureus
isolates were collected from hospital and community speci-
mens and were stored. Subsequent isolates from the same
patient and methicillin-resistant S. aureus (MRSA) screening
specimens were excluded.
Bacterial isolates
Identiﬁcation and antimicrobial susceptibility testing of S. aur-
eus isolates were performed using the Phoenix system (Bec-
ton Dickinson, Oxford, UK). All isolates were stored on
cryogenic beads at –70C until PCR was performed.
DNA extraction and real-time PCR of PVL genes
Isolates were inoculated from beads onto blood agar and
incubated at 35C overnight. DNA was extracted from the
cultured isolates using an achromopeptidase lysis procedure
[22]. Real-time PCR was used to detect a 138-bp region
spanning the lukS and lukF genes and all positive results were
conﬁrmed by sequence analysis. The original PCR target
described by Lina et al. [1] was shortened from 433 bp for
use on a real-time platform (Wallis M & Steer J, Plymouth
Hospitals NHS Trust, personal communication). Real-time
PCR was performed on a Rotor-Gene 3000 (Qiagen, Craw-
ley, UK) in a ﬁnal volume of 25 ll containing 1 · TaqMan
Universal PCR Master Mix (Applied Biosystems, Warrington,
UK), 0.9 lM of each primer (PVLF: 5¢-ATG TCC TTT CAC
TTT AAT TTC ATG AGT TTT-3¢; PVLR: 5¢-CAT GCT
ACT AGA AGA ACA ACA CAC TAT GG-3¢) and 0.2 lM
probe (–6 FAM AAA TGC GTT GTG TAT TCT AGA-
MGB). PCR cycling conditions were; one hold at 50C for
2 min followed by a second hold at 95C for 10 min fol-
lowed by 35 cycles of 95C for 15 s and 60C for 60 s. PCR
testing was performed by a researcher who was blind to the
exposure status of each bacterial sample.
Study measurements
Clinical proﬁle. Data were extracted on infection type from
the clinical information on the specimen request form. Speci-
mens from abscesses, impetigo, cellulitis, folliculitis, carbun-
cles and paronychias were grouped as skin and soft tissue
infections and analyzed separately from wound infections.
The source was deﬁned as the location of the patient when
the sample was taken and specimens from all sources except
hospital inpatients were classiﬁed as community-onset infec-
tions.
Risk factors for infection. Data were extracted on patient age,
gender, previous hospitalizations and history of S. aureus
infection or colonization. Hospital admission was recorded
as the total number and total duration of admission in days.
Outpatient attendance was deﬁned as total number of outpa-
tient appointments during the same period. Data on age,
hospital admission and outpatient attendance were included
as categorical variables reﬂecting the underlying distribution
of the data.
Statistical analysis
A sample size of 400 isolates was required to estimate a PVL
prevalence of 10% with a 95% CI of 7–14%. We used STATA,
version 10 (StataCorp, College Station, TX, USA), for all
data management and analyses. Descriptive statistics were
used to summarize the clinical and demographic characteris-
tics of the patients and the microbiological characteristics of
the sample. We estimated odds ratios for the association
between age, gender and PVL-SA disease and examined the
effect of healthcare contact, infection type, infection source
and previous isolation of S. aureus. A logistic regression
model was developed to identify risk factors for PVL disease
by sequentially adding in factors associated with outcome,
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starting with those most strongly associated, and assessing
for interaction with age. Results were presented as adjusted
ORs with 95% CI and p-values.
Results
Three hundred and ninety samples were available for analy-
sis. Thirty-eight of 390 specimens (9.7%, 95% CI 7.0–13.1%)
contained the genes for PVL, and 66/390 (16.9%, 95% CI,
11.8–18.6%) were methicillin resistant. 0.8% (3/390) of S. aur-
eus isolates contained PVL genes and were methicillin resis-
tant and 9.0% (35/390) contained PVL and were methicillin-
sensitive.
Clinical and demographic characteristics of PVL-SA positive
cases
20.8% (22/106) of isolates from skin and soft tissue infections
and 10% (1/10) from pus contained the PVL genes (Table 1).
PVL-SA strains were rare amongst infections that are
traditionally healthcare-associated such as ulcers (0/25).
Compared to individuals aged <20 years, the odds of
PVL-SA-related infection were highest in subjects aged
20–39 years, and reduced thereafter with increasing age (OR
3.2, 95% CI 1.1–8.7, p 0.02 (test for trend). Men had approx-
imately twice the odds compared to women of having
PVL-SA-related disease, [13.4% (29/216) vs. 5.3% (9/170),
OR 2.8, 95% CI 1.3–6.1, p 0.008]. Compared to infections
caused by PVL-SA negative strains, a higher proportion of
PVL-SA infections had their onset in the community [63.9%
(225/352) vs. 71.1% (27/38)].
PVL-SA infection was strongly associated with skin and
soft tissue disease and these samples were four-fold more
likely to contain the PVL genes compared to all other sample
types [20.8% (22/106) vs. 5.6% (16/284), OR 4.4, 95% CI
2.2–8.9, p <0.001]. The odds of PVL-SA disease were inde-
pendent of whether an isolate was methicillin-resistant and
whether the patients had a previous S. aureus infection.
Prior hospital contact and risk of PVL-SA-related disease
Patients who had not attended outpatients or been admitted
to hospital were at increased risk of PVL-SA infection. Com-
pared to patients who had spent at least 3 days in hospital in
the previous 18 months, patients who had not been admitted
were four-fold more likely to be infected with a PVL positive
strain [12.4% (26/209) vs. 3.2% (3/95), OR 4.4, 95% CI 1.3–
15.0] (Table 2). The odds of PVL infection were associated
with both the number of previous admissions and the dura-
tion of previous admissions. Compared to individuals who
frequently attended outpatients (more than ﬁve appoint-
ments in the last 18 months), patients who had not had an
outpatient appointment were more than three-fold as likely
to be infected with a PVL positive strain [11.7% (24/206) vs.
3.2% (3/94), OR 4.0, 95% CI 1.2–13.8].
In a multivariate logistic regression model, male gender
and skin and soft tissue disease were all independently asso-
ciated with PVL when adjusted for all other variables in the
model (p <0.05). There was no interaction with age for any
of the variables included in the multivariate analysis. Inclusion
of methicillin susceptibility data [methicillin-sensitive S. aureus
(MSSA) or MRSA] did not improve the model (p 0.7) and a
separate analysis stratiﬁed by S. aureus type identiﬁed
the same risk factors for PVL disease as in the combined
analysis.
Discussion
PVL associated with MRSA was rare in the present study,
but PVL associated with MSSA was common and almost
TABLE 1. Proportion of Panton–
Valentine leukocidin (PVL) positive
and patient age by specimen type
Sample typea n (%)




Skin/soft tissue infections 106 (27.2) 33.2 (17.1–58.3) 22/106 (20.8)
Wounds 120 (30.8) 60.9 (39.8–78.7) 10/120 (8.3)
Bacteraemias 3 (0.8) 73.6 (52.0–83.9) 0/3 (0)
Indwelling device 29 (7.4) 60.8 (47.6–67.3) 0/29 (0)
Osteomyelitis 3 (0.8) 54.1 (51.4–54.1) 0/3 (0)
Pus 10 (2.5) 61.6 (41.1–85.9) 1/10 (10.0)
Surface swabsb 62 (15.9) 50.8 (5.6–69.7) 2/62 (3.2)
Ulcers 25 (6.4) 68.3 (51.7–80.2) 0/25 (0)
Other 20 (5.1) 51.6 (39.7–72.7) 2/20 (10.0)
Respiratory 2 (0.5) 55.7 (13.9–97.5) 0/2 (10.0)
Unknown 10 (2.6) 24.3 (2.0–40.6) 1/10 (10.0)
Total 390 (100.0) 51.4 (28.4–72.9) 38/390 (9.7)
aSample type recorded directly from hospital microbiology database.
bSamples taken from the skin surface not labelled as skin and soft tissue infections, wounds or ulcers.
SA, Staphylococcus aureus.
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three-quarters of PVL-SA infections occurred in patients
based in the community.
Strengths and limitations of the study
The present study estimates the proportion of sampled
staphylococcal infections that contain the PVL genes and is
the ﬁrst in the UK to use an unselected sample of clinical
isolates.
Although we accurately measured the prevalence of PVL
amongst sampled infections, selection bias is likely because
not all infection types have an equal probability of being sam-
pled. Most patients with skin and soft tissue infections do
not have specimens taken for microbiological diagnosis. This
will tend to under-represent the total amount of skin and
soft tissue disease, and may under-estimate the overall prev-
alence of PVL-SA infections. Conversely, PVL production
may be up-regulated with low-dose ﬂucloxacillin, tending to
over-estimate the prevalence of PVL-SA amongst infections
treated with b-lactam antibiotics in the community [23].
The present study was limited by the quality and type of
data available in the patient hospital record. We could not
account for admissions or outpatient attendance at hospitals
other than the Royal Free Hampstead NHS Trust, and we
did not classify infections in hospitalized patients in the ﬁrst
48 h of admission as community-onset. These assumptions
may have respectively over and under-estimated the impor-
tance of community onset infections. We had incomplete
data on the patients’ past medical history, and no informa-
tion on antibiotic usage or behavioural risk factors. Because
we could not adjust for these factors in our analysis, they
may have confounded the associations we report. Data were
limited on the provenance of samples classiﬁed as surface
swabs, other and unknown origin, and PVL-SA prevalence
varied widely between these categories. Surface swabs are
mainly taken from superﬁcial skin lesions, whereas most
specimens classiﬁed as ‘other’ were obtained from individuals
with a wide range of systemic illnesses. This may explain the
heterogeneity in proportion of infections caused by strains
containing the PVL genes.
Our analysis suggests that MSSA with PVL genes are com-
mon and mainly cause skin and soft tissue infections that do
not require hospital admission. Our ﬁndings are likely to be
generalizable to other hospitals, suggesting that surveillance
data signiﬁcantly under-estimate the burden of PVL-SA infec-
tion. This has implications for UK infection control policy,
which advocates screening and/or treatment of PVL-SA cases
and their contacts [21] on the assumption that cases are
rare and serious. By contrast, if PVL cases are common and
usually not severe, widespread screening and decolonization
will be expensive, impractical and may expose many individu-
als to unnecessary antibiotic treatment.
PVL-associated disease was commoner in males and we
speculate that gender-speciﬁc physical factors, such as
increased body hair, might predispose to infection. We lack
data on individual patient outcomes, but almost half of PVL
strains were isolated from patients attending outpatients or
general practice, suggesting that they were sufﬁciently well
to receive treatment in the community. Because skin and
soft tissue infections are one of the commonest clinical pre-
sentations in general practice [24], we speculate that PVL
containing strains are responsible for a large number of non-
severe skin and soft tissue infections across the UK that are
managed effectively without hospital treatment.
The number of PVL-SA cases reported to the staphylo-
coccal reference unit has doubled between 2005 and 2006
[21], which may represent improved case ascertainment or
a real increase in the number of cases. A generalized
increase in PVL-SA prevalence might be expected to lead to
an increase in severe disease, and this is supported by
data from hospital episode statistics: admissions for severe
TABLE 2. Risk of PVL-SA infection
associated with hospital inpatient
admission or outpatient atten-
dance in the previous 18 months
Patient characteristics
PVL-SA positive
(n = 49) OR (95% CI) p-value
Medical history
Outpatient/inpatient in the last 18 months 18/220 (8.2%) 1.0 0.2
None 20/170 (11.8%) 1.5 (0.8–2.9)
Number of admissions to hospital
2 or more 3/95 (3.2%) 1.0 0.01a
1 9/86 (10.4%) 3.6 (0.9–14.0)
None 26/209 (12.4%) 4.4 (1.3–15.0)
Duration of admissions/days
>3 5/120 (4.2%) 1.0 0.02a
1–3 7/61 (11.5%) 3.0 (0.9–10.0)
None 26/209 (12.4%) 3.3 (1.2–8.4)
Number of outpatient appointments
6+ 3/94 (3.2%) 1.0 0.04a
1–5 11/90 (12.2%) 4.2 (1.1–16.0)
None 24/206 (11.7%) 4.0 (1.2–13.8)
aTest for trend.
PVL-SA, Panton–Valentine leukocidin containing Staphylococcus aureus.
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staphylococcal disease such as pneumonia and staphylococcal
scalded skin syndrome have increased ﬁve-fold between
1989 and 2004 [25].
Policy in this area must be informed by improved surveil-
lance to accurately determine the prevalence of PVL-SA
infection, coupled with an understanding of the contribution
of PVL and other toxins and virulence factors to disease
manifestation and severity. Until we identify patient-level risk
factors for severe disease, a universal policy is impractical.
We propose that guidance on decolonization and screening
of PVL-SA cases and contacts should be based on clinical
presentation and severity, and not simply on the presence of
the PVL gene.
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